Clinical Advances in Current Therapies and New Targeted Treatments of Systemic Lupus Erythematosus
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".
Deadline for manuscript submissions: closed (25 October 2021) | Viewed by 448
Special Issue Editor
Interests: autoimmune rheumatologic diseases; molecular mechanisms and treatment approach; applied immunological basic research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Systemic lupus erythematosus (SLE) represents the prototype of autoimmune diseases and is one of the most heterogeneous diseases that clinicians have to face in their clinical practice. This heterogeneity poses great challenges to its diagnosis and treatment and hampers therapeutic advances.
Although the short-term survival of SLE patients has improved substantially in the last decades, the health-related quality of life of these patients is still poor, due to progressive organ damage accrual and comorbidities which invalidate the long-term outcomes.
With the exception of belimumab, the current therapies for SLE are not target-specific and are often burdened with adverse effects. Earlier diagnosis and better management of specific organ manifestations and complications, such as lupus nephritis and neurological features, are the major unmet needs.
The search for novel molecular targets and innovative therapeutic approaches related to the array of clinical phenotypes is promising, making personalized medicine more realistic for SLE patients.
This Special Issue of the Journal of Clinical Medicine, entitled “Clinical Advances in Current Therapies and New Targeted Treatments of Systemic Lupus Erythematosus” is focused on novel treatments of SLE based on the most recent scientific discoveries. Researchers are invited to contribute with original works and reviews.
Dr. Marcella Prete
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- systemic lupus erythematosus
- innate and adaptive immunity
- autoreactive lymphocytes and antoantibodies
- biomarkers
- early diagnosis
- comorbidities
- biologic therapy
- new treatment strategies
